Skip to main content
Clinical Trials/CTRI/2021/12/038930
CTRI/2021/12/038930
Not yet recruiting
Phase 4

A prospective, randomized clinical study of two phakictoric implantablelenses to outcome in in patients with moderate to high myopia and astimatism.

Biotech Healthcare Holdings GmbH0 sites0 target enrollmentTBD

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Not specified
Sponsor
Biotech Healthcare Holdings GmbH
Status
Not yet recruiting
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
4 years ago
Study Type
Interventional

Investigators

Sponsor
Biotech Healthcare Holdings GmbH

Eligibility Criteria

Inclusion Criteria

  • 1\. Patients 21 years old or older.
  • 2\. Calculated IOL Power is within the range of the investigational IOLs
  • 3\. Corneal Cylindrical error within the range defined in the clinical investigation plan
  • 4\. Subject has monocular UCVA 0\.5 LogMAR or worse
  • 5\. Subject has had a stable refraction (±0\.5D; ±1\.0D for higher refractive errors), as expressed by manifest refraction spherical equivalent (MRSE) for a minimum 12 months prior to surgery, verified by consecutive refractions and/or medical records or prescription history.
  • 6\. Subject, who is a current contact lens wearer, needs to demonstrate a stable refraction (±0\.5D) expressed as MRSE, on two consecutive examination dates and stability of the refraction is determined by the following criteria:
  • a. Contact lenses were not worn for at least 2 weeks or 3 days prior to the first refraction.
  • b. Two refractions were performed at least 7 days apart.
  • 7\. Subject, who is expected to have residual postoperative cylindrical refractive error of \>\=1D, has been given the opportunity to experience his/her best spectacle vision with the anticipated correction.
  • 8\. Expected dilated pupil size at least large enough to visualize the axis marking.

Exclusion Criteria

  • 1\. Subject with acute and chronic disease or illness that would increase the operative risk or confound the outcomes of the evaluation.
  • 2\. Subject taking systematic medication that can confound the outcome of the study or increase the risk to the subject
  • 3\. Subject with ocular condition that may predispose the subject to future complications
  • 4\. Subject with previous intraocular or corneal surgery
  • 5\. Subject with less than the minimum endothelial cell density 2000 cells/mm² at the time of enrollment
  • 6\. Pregnant or planning to become pregnant, or is lactating during the course of the evaluation
  • 7\. Other condition associated with fluctuation of hormones
  • 8\. ACD measured from the endothelium lower than 2\.8 mm
  • 9\. Concurrent participation in another drug or device evaluation.
  • 10\. Any cataract of any grade

Outcomes

Primary Outcomes

Not specified

Similar Trials